Navigation Links
Sirion Therapeutics Supports Ophthalmic Education
Date:9/28/2007

- Company Provides Unrestricted Educational Grants to Support the 25th

Biennial Cornea Research Conference and the Inaugural DIRECT Dry AMD

Meeting -

TAMPA, Fla., Sept. 28 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today announced its support of the advancement of ocular innovation through its contributions of unrestricted educational grants to two upcoming ophthalmology conferences.

The first conference is Harvard University's Schepens Eye Research Institute's 25th Biennial Cornea Research Conference, taking place October 12 and 13, 2007 in Boston, MA. Schepens is the largest independent eye research institute in the nation, and an affiliate of Harvard Medical School. For additional information on this meeting, please visit their website at http://www.schepens.harvard.edu/cornea07.htm.

The second contribution will benefit the Duke University School of Medicine's Inaugural DIRECT Dry AMD Meeting, taking place October 25-27, 2007 in Durham, NC. This conference will update attendees with the latest information on Dry Age-related Macular Degeneration (AMD). For additional information on this meeting, please visit their website at http://www.directamd.com.

"Both of these conferences play a vital role in the awareness and advancement of research in ophthalmology," said Barry Butler, Sirion's President and Chief Executive Officer. "We appreciate the opportunity to support these institutions in advancing the treatment of ophthalmic disease."

About Sirion Therapeutics, Inc.

Sirion Therapeutics is a privately held biopharmaceutical company pursuing the discovery, development and commercialization of products addressing unmet medical needs in the protection and preservation of eyesight. Sirion's pipeline includes four late-stage opportunities: ganciclovir, a topical antiviral for herpetic keratitis which is awaiting an NDA filing in early 2008; difluprednate, a potent topical steroid in Phase III development for post-operative inflammation and uveitis; cyclosporine, a topical immunomodulator in Phase III testing for dry eye and fenretinide, a first-in-class oral vitamin A binding protein antagonist in Phase II development for geographic atrophy associated with dry AMD. For more information regarding Sirion, please visit Sirion's website at http://www.siriontherapeutics.com.


'/>"/>
SOURCE Sirion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. CDW buyer supports Berbee growth plans
3. Tech center supports energy-saving device for heat-treating plants
4. Inacom Supports Blackhawk Technology Mentor Program
5. Computer Card Supports Solo Doctor
6. Federal Funding Supports Small Business Innovation
7. Doyle urges support of higher education spending
8. Jump starting technology education
9. Stem cell and regenerative medicine center to aid education and commerce
10. Education is fundamental to Milwaukees growth
11. New book touts educational power of computer games
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
Breaking Biology Technology:
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
Breaking Biology News(10 mins):